Synchronization of the cytoplasmatic and the nuclear maturation of oocytes in vitro
US7192768B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 3, 2002 |
| Grant date | Mar 20, 2007 |
| Priority date | — |
| Expiry date | Sep 23, 2023 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P15/08
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention relates to a method for in vitro maturation of oocytes comprising the steps of: The invention also relates to an oocyte culture medium comprising a nuclear maturation inhibiting substance and comprising one or more gonadotropins and/or one or more growth factors. The nuclear maturation inhibiting substance may be a MAS antagonist or an FF-MAS synthesis inhibitor, preferably a cytochrome P450 lanosterol 14α-demethylase (P45014DM) inhibitor e.g. ketoconazole or 22-hydroxycholesterol. The one or more gonadotropins and/or one or more growth factors are preferably a combination of EGF and FSH and/or LH.The invention also relates to the use of a nuclear maturation inhibiting substance and one or more gonadotropins and/or one or more growth factors as described above for the preparation of a cell culture medium for in vitro maturation of oocytes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.